Predicting Success in the Biotech and Pharma Sectors Mark Schoenebaum of ISI Group earned two top spots on this year's All-America Research Team. Here he explains how he differentiates the good stocks from the bad. Related Articles Premium With a Thin IPO Calendar, Hedge Funds Are Zeroing In on Biopharma Stephen Taub Two Years In, Doha’s Venture Capital Gambit Gains Another Backer John Crabb Podcast- Structured Credit Spotlight: Collateralized Loan Obligations Sponsored by Fidelity Investments